Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

HHS - 852 - Center for Substance Abuse Prevention Drug Testing Advisory Board - Authorized by Law


Committee NameCenter for Substance Abuse Prevention Drug Testing Advisory BoardAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number852
Original Establishment Date10/27/1986Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*unlimited
Current Charter Date6/25/2020Designated Fed Officer Position Title*Senior Pharmacology and Regulatory Policy Advisor
Date Of Renewal Charter6/25/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Jennifer
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Fan
Establishment Authority*Authorized by LawDesignated Federal Officer Suffix
Specific Establishment Authority*42 U.S.C. § 217a, Section 222 of the Public Health Service ActDesignated Federal Officer Phone*(240) 276-1759
Effective Date Of Authority*10/27/1986Designated Federal Officer Fax*(240) 276-2610
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The CSAP Drug Testing Advisory Board's recommendations are an essential prerequisite for implementation of new science into regulation and practice.The CSAP Drug Testing Advisory Board provides advice to the Assistant Secretary for Mental Health and Substance Use, SAMHSA, as the Agency responsible for establishing federal agency workplace drug testing policies in accordance with Executive Order 12564, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency's drug testing activities and the drug testing laboratory certification program. The CSAP Drug Testing Advisory Board reviews SAMHSA's program for national laboratory certification for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It recommends areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. The CSAP Drug Testing Advisory Board also reviews the science associated with alternate specimen matrices and new drugs of abuse and the methods necessary to detect their presence.
How is membership balanced?*The CSAP Drug Testing Advisory Board consists of three nonvoting ex officio members who are officers or employees of the United States Government, as the Assistant Secretary for Mental Health and Substance Use, SAMHSA, determines necessary for the CSAP Drug Testing Advisory Board to effectively carry out its functions. The 10 public members are appointed by the Assistant Secretary, SAMHSA. Of the 10 appointed members, 8 are recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, and interpreting drug testing results. The appointed individuals should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug testing laboratory, related academic research, toxicological research, the Medical Review Officer community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs. Of the additional two appointed members, one shall represent users of SAMHSA’s certified drug testing laboratories and drug-free workplace programs and processes and one shall represent individuals tested in federal or federally-regulated workplace drug testing programs. All Board members who are not officers or employees (full-time or permanent part-time) of the United States Government shall serve as Special Government Employees. Appointments are made by paying close attention to experience and expertise as well as equitable gender representation, race/ethnicity representation, and geographic distribution. Board members advise SAMHSA executive leadership on policy and scientific and technical program development.
How frequent & relevant are cmte mtgs?*CSAP Drug Testing Advisory Board convened two times during FY 2020. Four meetings are tentatively scheduled for fiscal year 2021. The CSAP Drug Testing Advisory Board was charged during this fiscal year with evaluating the scientific supportability of the hair matrix as an alternative specimen for the inclusion in the Federal Workplace Drug Testing Programs. That work has proved challenging and time intensive. The CSAP Drug Testing Advisory Board also received federal drug testing updates from the Department of Transportation, the Department of Defense, the Nuclear Regulatory Commission, and the Federal Drug-Free Workplace Programs. In addition, the CSAP Drug Testing Advisory Board will continue to assist the Agency in recommending revisions to the Mandatory Guidelines for testing alternative specimens and additional Schedule II drugs, addressing the impact of new drugs of abuse in the workplace, and assessing the methods that are available to detect their use. The CSAP Drug Testing Advisory Board will review the Agency's National Laboratory Certification Program that was established as required by the Supplemental Appropriations Act of 1987 (Public Law 100-71) and as described in the Mandatory Guidelines.
Why advice can't be obtained elsewhere?*The CSAP Drug Testing Advisory Board is composed of both scientific and professional members who provide advice to the Assistant Secretary for Mental Health and Substance Use on improving the quality of services for forensic workplace drug testing, assessing the science and technology used in drug analyses, improving the quality of related laboratory services and systems for drug testing, generating standards for laboratory certification for federal workplace drug testing programs, and guiding national policy in these areas. There is no existing committee or other alternative mechanism that can provide the same expert advice as that provided by the CSAP Drug Testing Advisory Board.
Why close or partially close meetings?The closed portions of the Board's meetings involve discussions by the Board of proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs, unpublished and confidential research material, and the review of sensitive National Laboratory Certification Program information. These portions of the meetings are closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).
Recommendation RemarksNone.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentNA
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentIt is extremely difficult to determine the cost savings associated with identifying a federal employee as positive for an illicit substance.Grants Review CommentNA
Number Of Recommendations*38Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentFrom FY 1994 to FY 2020, the CSAP DTAB produced 38 recommendations.. The Oral Fluid Mandatory Guidelines was finalized and released in the Federal Register on October 25, 2019 with effective date of January 1, 2020.Access Agency WebsiteYes
% of Recs Fully Implemented*97.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentSince the beginning of the Board, approximately 97% of the Board's recommendations have been fully implemented without any changes. These recommendations concerned revisions to the Mandatory Guidelines, urine collection handbook, medical review officer manual, and other National Laboratory Certification Program documents and policies.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*3.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe Board's recommendations regarding changes in the scientific and administrative aspects of the Federal Workplace Drug Testing Programs are occasionally modified by the Department based on comments received from other Health and Human Services agencies; other federal departments, including the Department of Transportation, the Department of Defense, and the Nuclear Regulatory Commission; and the Office of Management and Budget.The hair recommendation is still in the evaluation process.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Feedback is provided to the Board members on the actions taken by the Agency on the Board's recommendations at each Board meeting, by e-mail, or by faxing or mailing documents to the Board members. Additionally, when policies are implemented, Board members are provided copies.Narrative Description*The Board provides advisory recommendations regarding improvements in the scientific aspects of forensic workplace drug testing, thereby, impacting on the Agency's efforts to prevent substance abuse among federal employees.
Hide Section - COSTS


Payments to Non-Federal Members*$4,800.00Est Payments to Non-Fed Members Next FY*$13,600.00
Payments to Federal Members*$32,431.48Est. Payments to Fed Members Next FY*$49,804.13
Payments to Federal Staff*$204,227.93Estimated Payments to Federal Staff*$208,873.86
Payments to Consultants*$8,151.00Est. Payments to Consultants Next FY*$8,232.51
Travel Reimb. For Non-Federal Members*$11,906.87Est Travel Reimb Non-Fed Members nextFY*$25,360.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$2,373.23Est Travel Reimb to Consultants Next FY*$2,396.96
Other Costs$39,290.00Est. Other Costs Next FY*$39,682.90
Total Costs$303,180.51Est. Total Next FY*$347,950.36
Federal Staff Support (FTE)*1.30Est. Fed Staff Support Next FY*1.30
Cost RemarksThe actual expenses in FY 2020 were significantly lower from FY 2019: i.e., amount of consultants used were reduced; off-site meetings were reduced; travel reimbursement for non-federal members reduced due to meetings held virtually due to the pandemic.Est Cost RemarksThe FY 2021 estimated costs are based on experienced actual costs from FY 2020, where there was a significant cost reduction in travel, off-site meetings and other costs. These costs could potentially increase if the Board would need to hold the meetings off site, and increase the use of consultants as it did in FY 19.
Hide Section - Interest Areas

Interest Areas

Applied Science
Applied Sciences
Basic Science
Food and Drugs
Food and Drugs
Federal Government
Drug Abuse Policy and Enforcement


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-036602Center for Substance Abuse Prevention Drug Testing Advisory Board2019
 COM-034806Center for Substance Abuse Prevention Drug Testing Advisory Board2018
 COM-001627Center for Substance Abuse Prevention Drug Testing Advisory Board2017
 COM-002317Center for Substance Abuse Prevention Drug Testing Advisory Board2016
 COM-004028Center for Substance Abuse Prevention Drug Testing Advisory Board2015
 COM-004506Center for Substance Abuse Prevention Drug Testing Advisory Board2014
 COM-005907Center for Substance Abuse Prevention Drug Testing Advisory Board2013
 COM-006631Center for Substance Abuse Prevention Drug Testing Advisory Board2012
 COM-008021Center for Substance Abuse Prevention Drug Testing Advisory Board2011
 COM-008864Center for Substance Abuse Prevention Drug Testing Advisory Board2010
 COM-010351Drug Testing Advisory Board2009
 COM-010779Drug Testing Advisory Board2008
 COM-012138Drug Testing Advisory Board2007
 COM-012824Drug Testing Advisory Board2006
 COM-013999Drug Testing Advisory Board2005
 COM-014508Drug Testing Advisory Board2004
 COM-015690Drug Testing Advisory Board2003
 COM-016732Drug Testing Advisory Board2002
 COM-017986Drug Testing Advisory Board2001
 COM-018415Drug Testing Advisory Board2000
 COM-019535Drug Testing Advisory Board1999
 COM-020494Drug Testing Advisory Board1998
 COM-021750Drug Testing Advisory Board1997